Skip to content
2000
image of Rosuvastatin Improved LDL Subfractions Profile in a Patient with Type 1 Diabetes Following a Ketogenic Diet: A Case Report

Abstract

Introduction

People on a ketogenic diet may develop an increase in low-density lipoprotein cholesterol (LDL-C), known as the lean mass hyper-responder (LMHR) phenotype. However, this increase does not necessarily correspond to a heightened cardiovascular (CV) risk, and optimal treatment strategies for high-risk individuals within this group remain uncertain.

Case Presentation

A 61-year-old man with type 1 diabetes developed the LMHR phenotype after adopting a ketogenic diet. An atherosclerotic plaque was discovered in the bulb of his left common carotid artery, reclassifying him into the secondary prevention category of CV disease. After the introduction of rosuvastatin 20 mg daily, his LDL-C subfraction profile changed from a more atherogenic type B phenotype to a less atherogenic type A phenotype without significantly decreasing overall LDL-C levels. This suggests that rosuvastatin provided a beneficial effect, complementing the metabolic improvements associated with the ketogenic diet, including better blood glucose and insulin control, potential prior reductions in small dense LDL-C and triglycerides, and an increase in high-density lipoprotein cholesterol (HDL-C). In this case, no trend toward a lower threshold was observed for the development of diabetic ketoacidosis.

Conclusion

Assessing LDL-C subfractions before and after the initiation of lipid-lowering therapy is essential in individuals who develop the lean mass hyper-responder (LMHR) phenotype, particularly in the presence of confirmed atherosclerosis. Given the markedly elevated LDL-C levels often observed in this population, it may be difficult to accurately evaluate the burden of atherogenic cholesterol and the extent of its reduction without subfraction analysis. In such cases, statin therapy appears to be a reasonable and potentially beneficial intervention, even among LMHR individuals.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611370578250621183337
2025-07-02
2025-09-26

  • From This Site

    /content/journals/cvp/10.2174/0115701611370578250621183337
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ference B.A. Braunwald E. Catapano A.L. The LDL cumulative exposure hypothesis: Evidence and practical applications. Nat. Rev. Cardiol. 2024 21 10 701 716 10.1038/s41569‑024‑01039‑5 38969749
    [Google Scholar]
  2. Chary A. Hedayati M. Review of laboratory methods to determine HDL and LDL subclasses and their clinical importance. Rev. Cardiovasc. Med. 2022 23 4 147 10.31083/j.rcm2304147 39076233
    [Google Scholar]
  3. Mach F. Baigent C. Catapano A.L. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020 41 1 111 188 10.1093/eurheartj/ehz455 31504418
    [Google Scholar]
  4. Silverman M.G. Ference B.A. Im K. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. JAMA 2016 316 12 1289 1297 10.1001/jama.2016.13985 27673306
    [Google Scholar]
  5. Blom D.J. Marais A.D. Raal F.J. Homozygous familial hypercholesterolemia treatment: New developments. Curr. Atheroscler. Rep. 2024 27 1 22 10.1007/s11883‑024‑01269‑5 39751968
    [Google Scholar]
  6. Norwitz N.G. Mindrum M.R. Giral P. Elevated LDL-cholesterol levels among lean mass hyper-responders on low-carbohydrate ketogenic diets deserve urgent clinical attention and further research. J. Clin. Lipidol. 2022 16 6 765 768 10.1016/j.jacl.2022.10.010 36351849
    [Google Scholar]
  7. Feldman D. Cholesterol code. 2018 Available from: https://cholesterolcode.com/are-you-a-lean-mass-hyper-responder/
  8. Firman C.H. Mellor D.D. Unwin D. Brown A. Does a ketogenic diet have a place within diabetes clinical practice? Review of current evidence and controversies. Diabetes Ther. 2024 15 1 77 97 10.1007/s13300‑023‑01492‑4 37966583
    [Google Scholar]
  9. Buehler L.A. Noe D. Knapp S. Isaacs D. Pantalone K.M. Ketogenic diets in the management of type 1 diabetes: Safe or safety concern? Cleve. Clin. J. Med. 2021 88 10 547 555 10.3949/ccjm.88a.20121 34598919
    [Google Scholar]
  10. Gardemann C. Knowles S. Marquardt T. Managing type 1 diabetes mellitus with a ketogenic diet. Endocrinol. Diabetes Metab. Case Rep. 2023 2023 3 23 0008 10.1530/EDM‑23‑0008 37584373
    [Google Scholar]
  11. Mikhailidis D.P. Elisaf M. Rizzo M. “European panel on low density lipoprotein (LDL) subclasses”: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 2011 9 5 533 571 10.2174/157016111796642661 21595628
    [Google Scholar]
  12. Koutnik AP Klein S Robinson AT Watso JC Efficacy and safety of long-term ketogenic diet therapy in a patient with type 1 diabetes. JCEM Case Rep 2024 2 7 luae102 10.1210/jcemcr/luae102 38989268
    [Google Scholar]
  13. Jaam M. Al-Naimi H.N. Haddad M.M. Abushanab D. Al-Badriyeh D. Comparative efficacy and safety among high-intensity statins. Systematic review and meta-analysis. J. Comp. Eff. Res. 2023 12 3 e220163 10.57264/cer‑2022‑0163 36847307
    [Google Scholar]
  14. Athyros V.G. Mikhailidis D.P. Papageorgiou A.A. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. 2004 57 7 728 734 10.1136/jcp.2003.012989 15220366
    [Google Scholar]
  15. de Zeeuw D. Anzalone D.A. Cain V.A. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial. Lancet Diabetes Endocrinol. 2015 3 3 181 190 10.1016/S2213‑8587(14)70246‑3 25660356
    [Google Scholar]
  16. Shepherd J. Kastelein J.J.P. Bittner V. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin. J. Am. Soc. Nephrol. 2007 2 6 1131 1139 10.2215/CJN.04371206 17942759
    [Google Scholar]
  17. Vogt L. Bangalore S. Fayyad R. Atorvastatin has a dose‐dependent beneficial effect on kidney function and associated cardiovascular outcomes: Post hoc analysis of 6 double‐blind randomized controlled trials. J. Am. Heart Assoc. 2019 8 9 e010827 10.1161/JAHA.118.010827 31020900
    [Google Scholar]
  18. Diamond D.M. Bikman B.T. Mason P. Statin therapy is not warranted for a person with high LDL-cholesterol on a low-carbohydrate diet. Curr. Opin. Endocrinol. Diabetes Obes. 2022 29 5 497 511 10.1097/MED.0000000000000764 35938780
    [Google Scholar]
  19. Budoff M. Manubolu V.S. Kinninger A. Carbohydrate restriction-induced elevations in ldl-cholesterol and atherosclerosis. JACC Adv 2024 3 8 101109 10.1016/j.jacadv.2024.101109 39372369
    [Google Scholar]
  20. Iatan I. Huang K. Vikulova D. Ranjan S. Brunham L.R. Association of a low-carbohydrate high-fat diet with plasma lipid levels and cardiovascular risk. JACC Adv 2024 3 6 100924 10.1016/j.jacadv.2024.100924 39081652
    [Google Scholar]
  21. Popiolek-Kalisz J. Ketogenic diet and cardiovascular risk – state of the art review. Curr. Probl. Cardiol. 2024 49 3 102402 10.1016/j.cpcardiol.2024.102402 38232923
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611370578250621183337
Loading
Rosuvastatin Improved LDL Subfractions Profile in a Patient with Type 1 Diabetes Following a Ketogenic Diet: A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0115701611370578250621183337
/content/journals/cvp/10.2174/0115701611370578250621183337
/content/journals/cvp/10.2174/0115701611370578250621183337
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: Type 1 diabetes ; low-density lipoprotein cholesterol subfractions ; lean mass hyper-responder phenotype ; ketogenic diet ; statin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test